A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid Leukemia

Abstract excerpt

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy that continues to have poor prognosis despite recent therapeutic advances. Venetoclax (Ven), a BCL2-inhibitor has shown a high response rate in AML; however, relapse is invariable due to mitochondrial dysregulation that includes upregulation of the antiapoptotic protein MCL1, a central mechanism of Ven resistance (Ven-res). We have previously dem...

Topics

Open a Topic to create a Post that cites this publication.

• Acute Myeloid Leukemia Research
• Bridged Bicyclo Compounds, Heterocyclic
• fms-Like Tyrosine Kinase 3
• Histone Deacetylase Inhibitors Research
• Mitogen-Activated Protein Kinases
• Myeloid Cell Leukemia Sequence 1 Protein
• Protein Tyrosine Phosphatase, Non-Receptor Type 11
• Pyrimidines

Identifiers and source

Literature Corpus work

c8d2a899-ad24-5911-b799-1675380390e6

DOI

10.1101/2024.08.05.599788